Events

Matchmaking Event for EU Missions - New Topics (2022 calls)
MAY
Thu
19
10:00 - 18:00

This was 3 years ago

Location

Online

Programmes
Health Climate, Energy, Mobility Agro-Food, Environment Missions

Back-to-back with the Commission's EU Missions Info Days, a virtual partnering event is organised on the new 2022 EU Missions calls of Horizon Europe. This event gives you the opportunity to get in touch with potential consortium partners for the forthcoming calls  that have been published on 10 May 2022 in the amended EU Missions work programme 2021-2022. The event will include on-line bilateral meetings with partners interested in the same topics for 2022 calls.

More information and registration on the event website. The deadline to register is 17 May.

The event is organised by BRIDGE2HE, the Network of Horizon Europe National Contact Points. 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.